Viropharma, Inc. (VPHM) Tops Q4 EPS by 19c, Sales Top Expectations
Tweet
Share
E-mailGet Alerts VPHM Hot Sheet
Price: $49.96 --0%
Financial Fact:
Research and development: 18.09M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Research and development: 18.09M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Viropharma, Inc. (NASDAQ: VPHM) reported Q4 EPS of $0.61, $0.19 better than the analyst estimate of $0.42. Revenue for the quarter came in at $145.6 million versus the consensus estimate of $144.65 million.
Viropharma, Inc. sees FY2012 revenue of $600-$660 million.
For earnings history and earnings-related data on Viropharma, Inc. (VPHM) click here.
Viropharma, Inc. sees FY2012 revenue of $600-$660 million.
For earnings history and earnings-related data on Viropharma, Inc. (VPHM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
